Related Experiment Video
Updated: May 7, 2026
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Polymorphisms of HPC2/ELAC2 and SRD5A2 (5α-Reductase Type II) Genes in Prostate Cancer
M Izmirli1, B Arikan, Y Bayazit
1Department of Medical Biology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.
Balkan Journal of Medical Genetics : BJMG
|September 21, 2013
Summary
Genetic variations in HPC2/ELAC2 and SRD5A2 genes increase prostate cancer risk in Turkish men. Specifically, Ser217Leu and Ala49Thr polymorphisms are linked to higher cancer susceptibility.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- Prostate cancer is a significant health concern characterized by malignant cell proliferation.
- Genetic factors, including HPC2/ELAC2 and SRD5A2 genes, are implicated in prostate cancer predisposition.
- Polymorphisms in these genes may influence an individual's risk of developing prostate cancer.
Purpose of the Study:
- To investigate the association between specific polymorphisms in the HPC2/ELAC2 and SRD5A2 genes and prostate cancer risk.
- To analyze the Ser217Leu and Ala541Thr variants of HPC2/ELAC2 and Ala49Thr and Val89Leu variants of SRD5A2.
- To evaluate these genetic associations within the Turkish male population.
Main Methods:
- Utilized the polymerase chain reaction (PCR) technique to identify specific gene polymorphisms.
- Employed appropriate restriction enzymes for genotyping.
- Conducted a case-control study analyzing genetic variations in relation to prostate cancer status.
Main Results:
- The Ser217Leu polymorphism in the HPC2/ELAC2 gene was significantly associated with an increased risk of prostate cancer (OR 2.7, 95% CI 1.6-4.8).
- The Ala49Thr polymorphism in the SRD5A2 gene also showed a significant association with elevated prostate cancer risk (OR 2.4, 95% CI 1.2-4.9).
- No significant association was found for HPC2/ELAC2 Ala541Thr and SRD5A2 Val89Leu polymorphisms.
Conclusions:
- Specific polymorphisms in the HPC2/ELAC2 (Ser217Leu) and SRD5A2 (Ala49Thr) genes are identified as risk factors for prostate cancer in Turkish men.
- These findings contribute to understanding the genetic basis of prostate cancer in this population.
- Further research may explore these genetic markers for risk stratification and personalized prevention strategies.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...